

PRODUCT INFORMATION & ELISA MANUAL

IL-17/IL-17A Antibody Pair [HRP] NBP2-79384

Sample Insert for reference use only

Matched Antibody Pair utilized in an Enzyme-linked Immunosorbent Assay for quantitative detection of Human IL-17/IL-17A.

For research use only.

Not for diagnostic or therapeutic procedures.

www.novusbio.com - P: 303.730.1950 - P: 888.506.6887 - F: 303.730.1966 - technical@novusbio.com

Novus kits are guaranteed for 6 months from date of receipt

BACKGROUND

IL17, also known as IL17a, is a cytokine belongs to the IL-17 family. Cytokines are proteinaceous signaling compounds that are major mediators of the immune response. They control many different cellular functions including proliferation, differentiation and cell survival/apoptosis but are also involved in several pathophysiological processes including viral infections and autoimmune diseases. Cytokines are synthesized under various stimuli by a variety of cells of both the innate (monocytes, macrophages, dendritic cells) and adaptive (T- and B-cells) immune systems. The IL-17 family of cytokines includes six members, IL-17/IL-17A, IL-17B, IL-17C, IL-17D, IL-17E/IL-25, and IL-17F, which are produced by multiple cell types. IL-17 regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.

PRINCIPLE OF THE TEST


The Novus Biologicals IL-17/IL-17A Antibody Pair [HRP] is a solid phase sandwich ELISA (Enzyme-Linked Immunosorbent Assay). It utilizes a monoclonal antibody specific for Human IL-17/IL-17A coated on a 96-well plate. Standards and samples are added to the wells, and any Human IL-17/IL-17A present binds to the immobilized antibody. The wells are washed and a horseradish peroxidase conjugated mouse anti- Human IL-17/IL-17A monoclonal antibody is then added, producing an antibody-antigenantibody "sandwich". The wells are again washed and TMB substrate solution is loaded, which produces color in proportion to the amount of Human IL-17/IL-17A present in the sample. To end the enzyme reaction, the stop solution is added and absorbances of the microwell are read at 450 nm.

INTENDED USE

◆ The Human IL-17/IL-17A Antibody Pair [HRP] is for the quantitative determination of Human IL17A/IL-17A/IL17.

 This IL-17/IL-17A Antibody Pair [HRP] contains the basic components required for the development of sandwich ELISAs.

ASSAY PROCEDURE SUMMARY



This antibody pair has been configured for research use only and is not to be used in diagnostic procedures.

MATERIALS PROVIDED

Bring all reagents to room temperature before use.

Capture Antibody – 1 mg/mL of mouse anti-Human IL-17/IL-17A monoclonal antibody (in PBS, pH 7.4). Dilute to a working concentration of 1 μ g/mL in PBS before coating.

Detection Antibody – 0.2 mg/mL of mouse anti-Human IL-17/IL-17A monoclonal antibody conjugated to horseradish-peroxidase (HRP) (in PBS, 50 % HRP-Protector, pH 7.4, store at 4° C). Dilute to working concentration of 0.25 µg/mL in detection antibody dilution buffer before use.

Standard – Each vial contains 4.7 ng of recombinant Human IL-17/IL-17A. Reconstitute with 1 mL detection antibody dilution buffer. After reconstitution, store at -20° C to -80° C in a manual defrost freezer. A seven-point standard curve using 2-fold serial dilutions in sample dilution buffer, and a high standard of 75 pg/mL is recommended.

SOLUTIONS REQUIRED

PBS - 136.9 mM NaCl, 10.1 mM Na₂HPO₄, 2.7 mM KCl, 1.8 mM KH₂PO₄, pH 7.4, 0.2 μm

filtered

TBS - 20 mM Tris, 150 mM NaCl, pH 7.4

Wash Buffer - 0.05% Tween20 in TBS, pH 7.2 - 7.4

Blocking Buffer - 2% BSA in Wash Buffer

Sample dilution buffer - 0.1% BSA in wash buffer, pH 7.2 - 7.4, 0.2 µm filtered

Detection antibody dilution buffer - 0.5% BSA in wash buffer, pH 7.2 - 7.4, 0.2 µm filtered

Substrate Solution : To achieve best assay results, fresh substrate solution is recommended

Substrate stock solution - 10mg / ml TMB (Tetramethylbenzidine) in DMSO

Substrate dilution buffer - 0.05M Na₂HPO₄ and 0.025M citric acid ; adjust pH to 5.5

Substrate working solution - For each plate dilute 250 µl substrate stock solution in 25ml

substrate dilution buffer and then add 80 μ I 0.75% H₂O₂, mix it well

Stop Solution - 2 N H₂SO₄

PRECAUTION

The Stop Solution suggested for use with this antibody pair is an acid solution. Wear eye, hand, face, and clothing protection when using this material.

STORAGE

Capture Antibody: Aliquot and store at -20 $^{\circ}$ C to -80 $^{\circ}$ C for up to 6 months from date of receipt. Avoid repeated freeze-thaw cycles.

Detection Antibody: Store at 4° C and protect it from prolonged exposure to light for up to 6 months from date of receipt. **DO NOT FREEZE!**

Standard: Store lyophilized standard at -20 $^{\circ}$ C to -80 $^{\circ}$ C for up to 6 months from date of receipt. Aliquot and store the reconstituted standard at -80 $^{\circ}$ C for up to 1 month. Avoid repeated freeze-thaw cycles.

GENERAL ELISA PROTOCOL

Plate Preparation

1. Dilute the capture antibody to the working concentration in PBS. Immediately coat a 96-well microplate with 100 μ L per well of the diluted capture antibody. Seal the plate and incubate overnight at 4 °C.

2. Aspirate each well and wash with at least 300µl wash buffer, repeating the process two times for a total of three washes. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any remaining wash buffer by inverting the plate and blotting it against clean paper towels. 3.Block plates by adding 300 µL of blocking buffer to each well. Incubate at room temperature for a minimum of 1 hour.

4.Repeat the aspiration/wash as in step 2. The plates are now ready for sample addition.

Assay Procedure

1.Add 100 μ L of sample or standards in sample dilution buffer per well. Seal the plate and incubate 2 hours at room temperature.

2. Repeat the aspiration/wash as in step 2 of plate preparation.

3. Add 100 µL of the detection antibody, diluted in antibody dilution buffer, to each well. Seal the plate and incubate 1 hour at room temperature.

4. Repeat the aspiration/wash as in step 2 of plate preparation.

5.Add 200 μ L of substrate solution to each well. Incubate for 20 minutes at room temperature (**if substrate solution is not as requested, the incubation time should be optimized**). Avoid placing the plate in direct light.

6. Add 50 μ L of stop solution to each well. Gently tap the plate to ensure thorough mixing. 7. Determine the optical density of each well immediately, using a microplate reader set to 450 nm.

CALCULATION OF RESULTS

• Calculate the mean absorbance for each set of duplicate standards, controls and samples. Subtract the mean zero standard absorbance from each.


• Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on the graph.

•To determine the concentration of the unknowns, find the unknowns' mean absorbance value on the yaxis and draw a horizontal line to the standard curve. At the point of intersection, draw a vertical line to the x-axis and read the concentration. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

•Alternatively, computer-based curve-fitting statistical software may also be employed to calculate the concentration of the sample.

TYPICAL DATA

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.



| Concentration (pg/mL) | Zero standard subtracted OD | | | | |
|------------------------|-----------------------------|--|--|--|--|
| 0 | 0 | | | | |
| 1.17 | 0.046 | | | | |
| 2.34 | 0.083 | | | | |
| 4.69 | 0.173 | | | | |
| 9.38 | 0.353 | | | | |
| 18.75 | 0.674 | | | | |
| 37.5 | 1.337 | | | | |
| 75 | 2.317 | | | | |

PERFORMANCE CHARACTERISTIC

SENSITIVITY

The minimum detectable dose of Human IL-17/IL-17A was determined to be approximately **1.17 pg/ml**. This is defined as at least three times standard deviations above the mean optical density of 10 replicates of the zero standard.

TROUBLE SHOOTING

| Problems | Possible Sources | Solutions | | | |
|----------------------|---|--|--|--|--|
| | Incorrect or no Detection Antibody was added | Add appropriate Detection Antibody and continue | | | |
| No signal | Substrate solution was not added | Add substrate solution and continue | | | |
| | Incorrect storage condition | Check if the kit is stored at recommended condition and used before expiration date | | | |
| | Standard was incompletely reconstituted or was inappropriately stored | Aliquot reconstituted standard and store at -80 $^\circ\!\!\!\mathrm{C}$ | | | |
| Poor Standard | Imprecise / inaccurate pipetting | Check / calibrate pipettes | | | |
| Curve | Incubations done at inappropriate temperature, timing or agitation | Follow the general ELISA protocol | | | |
| | Background wells were contaminated | Avoid cross contamination by using the sealer appropriately | | | |
| | The concentration of antigen in samples was too low | Enriching samples to increase the concentration of antigen | | | |
| Poor detection value | Samples were ineffective | Check if the samples are stored at cold environment. Detect samples in timely manner | | | |
| | | Use multichannel pipettes without touching the reagents on the plate | | | |
| High Background | Insufficient washes | Increase cycles of washes and soaking time between washes | | | |
| | TMB Substrate Solution was contaminated | TMB Substrate Solution should be clear and colorless prior to addition to wells | | | |
| | Materials were contaminated. | Use clean plates, tubes and pipettes tips | | | |
| Non-specificity | Samples were contaminated | Avoid cross contamination of samples | | | |
| | The concentration of samples was too high | Try higher dilution rate of samples | | | |

| | ELISA Plate Template | | | | | | | | | | | |
|---|----------------------|---|---|---|---|---|---|---|---|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| Α | | | | | | | | | | | | |
| В | | | | | | | | | | | | |
| С | | | | | | | | | | | | |
| D | | | | | | | | | | | | |
| E | | | | | | | | | | | | |
| F | | | | | | | | | | | | |
| G | | | | | | | | | | | | |
| Н | | | | | | | | | | | | |

Human IL-17/IL-17A Antibody Pair [HRP] Notes